AMDIS

Pioneering New Beginnings

AMDIS Health Sciences Middle East stands as a privately owned entity headquartered in the United Arab Emirates, committed to the advancement, in-licensing and strategic marketing of specialty innovative therapeutics. Our distinct focus lies in the realm of value addition to life-changing treatments, where we place a premium on innovation and the delivery of value-added products that specifically cater to the healthcare needs of patients in our region. Our dedicated team is actively engaged in the development of cutting-edge therapeutics, coupled with a strategic approach to in-licensing initiatives that align with our commitment to providing comprehensive healthcare solutions. At the core of our mission is a steadfast dedication to fostering innovation and delivering products that go beyond conventional standards. By leveraging our expertise and industry insights, we strive to introduce novel therapeutic options and value-driven pharmaceuticals that contribute significantly to the well-being of individuals in the Middle East.

Our Vision

Our Vision

In our relentless pursuit of advancing product accessibility, we are dedicated to fostering collaborations with research-driven organizations worldwide. This strategic approach aims to expedite the introduction of sophisticated, value-added products that outperform existing solutions. Our distinctive portfolio consists of top-tier pharmaceutical therapeutics, cutting edge functional compounds known for their exceptional quality and intricate manufacturing processes. This diverse range serves as the cornerstone of our targeted growth strategy.

“We aspire to redefine the future of health care in the region and establish ourselves as the preferred partner by setting a new standard.”

Our Objective and Significance

At AMDIS, we employ effective go-to-market strategies, complemented by a profound regulatory comprehension, to expedite the introduction of innovative products to discerning patients within our region. The governance framework at AMDIS is designed to facilitate the scalability of our portfolio in our current operational domains while also fostering the exploration of opportunities in additional geographical areas. Renowned for our swift decision-making processes, AMDIS attributes this efficiency to the wealth of experience within our management team and the streamlined hierarchy stemming from our privately held corporate structure. This unique organizational setup allows us to adapt quickly to market dynamics and seize opportunities with agility.

Our Objective and Significance

Premjith Balakrishnan

(CEO and Managing Director)

Our Management

Mr. Premjith Balakrishnan possesses over a decade of exemplary leadership experience in the Pharmaceutical, Nutraceutical and Medical Device industries. As a Co-Founder of Synergy Pharma in the UAE, he played a pivotal role in establishing the company’s presence. His significant contributions include serving as the Director of Microsynergy Pharmaceuticals in the UAE and co-creating Unique Life Medicines Trading, a specialized business unit with a focus on injectables.

Additionally, Mr. Balakrishnan held the position of Director at Ishaanav Nutraceuticals in India, a Contract Manufacturing Organization (CMO) specializing in Nutraceuticals. Currently, he serves as the CEO and Director of Amdis Health Sciences in India. Simultaneously, he holds the position of Managing Director at Aurora Farmabio in India, where he oversees Business-to-Business (B2B) activities with a focus on Contract Development and Manufacturing Organization (CDMO) services. His responsibilities extend to licensing both in and out of functional ingredients, as well as handling Niche Active Pharmaceutical Ingredients (APIs) for both Indian and Global markets.

Moreover, he significantly raised Vitamin D awareness in the UAE and GCC, introducing the Vita D range, Sundrops and Ultra D range. In Gastroenterology, he also launched products like Esoxx, Flatuna, Medirefleux and Simecol across the GCC.

Recognizing nutritional gaps, he introduced successful brands like Heme Bears, Mg Vita, and Globifer Forte. Focusing on OTC opportunities, he launched well-received brands like Oraheal, Privituss, and Camdol Range. At Microsynergy Pharmaceuticals, UAE, Mr. Balakrishnan introduced blockbuster Pain and Allergy management brands, including Coxib, Hicet Erostin, Carmellose HA and Serrodase. The success of Fosmol and Tafixyl brands established Microsynergy as a formidable presence in the Gynec and Urology segment. Played a key role in the strategic decision to form a manufacturing facility in Dubai, significantly enhancing the scalability of Microsynergy’s pharmaceutical business.

Our Crew

A seasoned and dynamic leadership team oversees Finance, Administration, Marketing, Sales, Regulatory Affairs, and Business Development. In Finance, experts optimize fiscal strategies for growth. Administration ensures seamless operations. Marketing and Sales, led by strategic minds, drive brand visibility and revenue growth. Regulatory Affairs ensures compliance and corporate responsibility. Business Development leaders identify growth opportunities. Together, this cohesive team navigates the business landscape with industry knowledge, strategic insight, and hands-on expertise for sustained success.